Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.54 |
| ▸ | FAAH | O00519 | 4/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.42 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.42 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4322242 | 1.00 | PTGS2 (0.54) | PTGS2FAAHPTGS1MAPK14CYP4F2 | |
| SCHEMBL4330527 | 0.94 | FAAH (0.52) | PTGS2FAAHCYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL4334690 | 0.92 | FAAH (0.48) | PTGS2FAAHMAPK14CYP4F2CYP4A11 | |
| SCHEMBL4327560 | 0.92 | FAAH (0.48) | PTGS2FAAHMAPK14CYP4F2CYP4A11 | |
| SCHEMBL27047305 | 0.91 | PTGS2 (0.53) | PTGS2FAAHPTGS1MAPK14PTGDR2 | |
| SCHEMBL4331308 | 0.90 | PPARD (0.49) | PTGS2FAAHCYP4F2CYP4A11PTGDR2 | |
| SCHEMBL4329549 | 0.90 | PPARD (0.49) | PTGS2FAAHCYP4F2CYP4A11PTGDR2 | |
| SCHEMBL4325328 | 0.86 | PTGS2 (0.58) | PTGS2FAAHPTGS1MAPK14PTGDR2 | |
| SCHEMBL4325159 | 0.86 | PTGS2 (0.58) | PTGS2FAAHPTGS1MAPK14PTGDR2 | |
| SCHEMBL4322299 | 0.82 | HDAC1 (0.55) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7521563-B2 | Hydroxamic acid derivative and medicine containing the same as active ingredient | SHIZUOKA COFFEIN CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| US-20070208065-A1 | Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient | SHIZUOKA COFFEIN CO., LTD. (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1787986-A1 | HYDROXAMIC ACID DERIVATIVE AND MEDICINE CONTAINING THE SAME AS ACTIVE INGREDIENT | SHIZUOKA COFFEIN CO., LTD. (JP) | 2007-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208065-A1 | Hydroxamic Acid Derivative and Medicine Containing the Same as Active Ingredient | IL6, IL1A, TNF | PTGS2 45/4885FAAH 2052/4885PTGS1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.